Correlation between different levels of thyroid autoantibodies and immune checkpoint inhibitor-associated thyroid dysfunction

Patients with malignant tumors who had high levels of TPOAb and/or TRAb before treatment were more likely to develop thyroid immune-related adverse events (irAEs) after treatment. The importance of screening for baseline thyroid autoantibodies in predicting thyroid irAEs needs to be clearly understood, and close monitoring and notification to patients should be carried out, along with prior intervention.